Rapid Diagnostic Test Evaluated for Human Malaria Species
|
By LabMedica International staff writers Posted on 04 Jul 2012 |
|
A rapid diagnostic test (RDT) for malaria parasites has been evaluated and compared with other methods in a reference setting.
The three-band rapid diagnostic test detects Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH (pan-pLDH).
Scientists at Maastricht University (Netherlands) carried out a retrospective and a prospective study to assess with 498 stored and 77 fresh blood samples obtained from international travelers suspected of malaria. Both panels comprised all four Plasmodium species; the retrospective panel comprised also samples negative for malaria. The retrospective panel had been obtained between February 1996 and May 2011. The reference method was microscopy corrected by polymerase chain reaction (PCR). The prospective panel was run side-to-side with two other RDTs.
In the retrospective evaluation, overall sensitivity for the 247 P. falciparum samples was 94.7%, reaching 98.7% for parasite densities greater than 1,000/μL. Most false negative results occurred among samples with pure gametocytaemia and at parasite densities less than or equal to 100/μL. None of the 96 negative samples showed visible test lines. Sensitivities for the 70 P. vivax, 69 P. ovale and 16 P. malariae were 74.3%, 31.9% and 25.0% respectively. Overall, Pf-pLDH test lines showed higher line intensities compared to the pan-pLDH lines, with 67.9% and 23.0% medium and strong line intensities for P. falciparum.
In the prospective panel, the CareStart pLDH RDT (AccessBio Inc.; Monmouth, NJ, USA) showed higher sensitivities for P. falciparum compared to OptiMAL (Pf-pLDH/pan-pLDH, BioRad; Marnes-la-Coquette, France) and lower sensitivities for P. falciparum as compare to SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH; Standard Diagnostics; Hagal-Dong, Korea). Wrong species identification occurred in 10 (2.5%) samples and was mainly due to P. vivax samples reacting with the Pf-pLDH test line.
The authors concluded that CareStart pLDH may be an alternative to other well-described HRP-2 three band RDTs in the diagnostic setting in non-endemic areas. Despite being better than the other two RDTs that were run side by side, it should be noted that its performance for the detection of P. ovale and P. malariae is mediocre. The study was published on June 18, 2012, in the Malaria Journal.
Related Links:
Maastricht University
AccessBio Inc.
BioRad
The three-band rapid diagnostic test detects Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH (pan-pLDH).
Scientists at Maastricht University (Netherlands) carried out a retrospective and a prospective study to assess with 498 stored and 77 fresh blood samples obtained from international travelers suspected of malaria. Both panels comprised all four Plasmodium species; the retrospective panel comprised also samples negative for malaria. The retrospective panel had been obtained between February 1996 and May 2011. The reference method was microscopy corrected by polymerase chain reaction (PCR). The prospective panel was run side-to-side with two other RDTs.
In the retrospective evaluation, overall sensitivity for the 247 P. falciparum samples was 94.7%, reaching 98.7% for parasite densities greater than 1,000/μL. Most false negative results occurred among samples with pure gametocytaemia and at parasite densities less than or equal to 100/μL. None of the 96 negative samples showed visible test lines. Sensitivities for the 70 P. vivax, 69 P. ovale and 16 P. malariae were 74.3%, 31.9% and 25.0% respectively. Overall, Pf-pLDH test lines showed higher line intensities compared to the pan-pLDH lines, with 67.9% and 23.0% medium and strong line intensities for P. falciparum.
In the prospective panel, the CareStart pLDH RDT (AccessBio Inc.; Monmouth, NJ, USA) showed higher sensitivities for P. falciparum compared to OptiMAL (Pf-pLDH/pan-pLDH, BioRad; Marnes-la-Coquette, France) and lower sensitivities for P. falciparum as compare to SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH; Standard Diagnostics; Hagal-Dong, Korea). Wrong species identification occurred in 10 (2.5%) samples and was mainly due to P. vivax samples reacting with the Pf-pLDH test line.
The authors concluded that CareStart pLDH may be an alternative to other well-described HRP-2 three band RDTs in the diagnostic setting in non-endemic areas. Despite being better than the other two RDTs that were run side by side, it should be noted that its performance for the detection of P. ovale and P. malariae is mediocre. The study was published on June 18, 2012, in the Malaria Journal.
Related Links:
Maastricht University
AccessBio Inc.
BioRad
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
TORCH Infections Test
TORCH Panel
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
